View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. pharma services oehler
3 September 2019

Information on Variation Application Fee Capping

Swissmedic has introduced the principle of capping in response to the rise of fees for variations with revision of the law and so the following should be noted:

(1) To determine caps, the current Ordinance on Fees is always decisive. It is irrelevant whether authorisation of the medicinal product took place before or after the revision of the Ordinance on Fees.

(2) Should the authorisation category, for example, NA-NAS, KAS with / without innovation, major variation / new pharmaceutical form of the medicinal product not be clear, Swissmedic (Case Manager) can investigate the issue. The same applies to medicinal products. In particular, the authorisation categories that did not yet exist at the time of authorisation or where the categorisation was different, for example, KAS with / without innovation classification.

(3) Caps always refer to the flat-rates. Surcharges and discounts (FTAP, PPN, Art. 13, Art. 14) are not applicable. Discounts given based on Art. 13 or Orphan Drugs do not factor into the capping process.

pharma services oehler supports clients with food-related applications and activities with competent authorities. For more information on their products and services, please fill out the enquiry form attached to this page.

This white paper highlights what it takes to bring a drug to the Swiss market, including the marketing authorisation application MAA), preapproval and launch preparation...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology